Image-guided botulinum toxin injection in the lateral abdominal wall prior to abdominal wall reconstruction surgery: review of techniques and results.


Journal

Skeletal radiology
ISSN: 1432-2161
Titre abrégé: Skeletal Radiol
Pays: Germany
ID NLM: 7701953

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 15 05 2020
accepted: 29 06 2020
revised: 25 06 2020
pubmed: 6 7 2020
medline: 25 6 2021
entrez: 5 7 2020
Statut: ppublish

Résumé

Ventral hernias represent the most common complication after abdominal surgery. Loss of domain and/or large ventral hernias in patients are especially challenging for surgeons to manage, but preoperative image-guided botulinum toxin injection has emerged as an effective adjunct to abdominal wall surgery. Loss of domain is caused by chronic muscle retraction of the lateral abdominal wall and leads to an irreducible protrusion of abdominal viscera into the hernia sac. Botulinum toxin can be used in the oblique muscles as a chemical component relaxation technique to aid abdominal wall reconstruction. Intramuscular botulinum toxin injection causes functional denervation by blocking neurotransmitter acetylcholine release resulting in flaccid paralysis and elongation of lateral abdominal wall muscles, increasing the rate of fascial closure during abdominal wall reconstruction, and decreasing recurrence rates. In total, 200-300 units of onabotulinumtoxinA (Botox®) or 500 units of abobotulinumtoxinA (Dypsort®) in a 2:1 dilution with normal saline is most commonly used. Botulinum toxin can be injected with ultrasonographic, EMG, or CT guidance. Injection should be performed at least 2 weeks prior to abdominal wall reconstruction, for maximal effect during surgery. At minimum, botulinum toxin should be injected into the external and internal oblique muscles at three separate sites bilaterally for a total of six injections. Although botulinum toxin use for abdominal wall reconstruction is currently not indicated by the Food and Drug Administration, it is safe with only minor complications reported in literature.

Identifiants

pubmed: 32621063
doi: 10.1007/s00256-020-03533-6
pii: 10.1007/s00256-020-03533-6
doi:

Substances chimiques

Neuromuscular Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Références

Kingsnorth A, Le Blanc K. Hernias: inguinal and incisional. Lancet (London, England). 2003;362(9395):1561–71.
doi: 10.1016/S0140-6736(03)14746-0
Deerenberg EB, Harlaar JJ, Steyerberg EW, et al. Small bites versus large bites for closure of abdominal midline incisions (STITCH): a double-blind, multicentre, randomised controlled trial. Lancet. 2015;386(10000):1254–60.
pubmed: 26188742 doi: 10.1016/S0140-6736(15)60459-7
Jairam AP, Timmermans L, Eker HH, et al. Prevention of incisional hernia with prophylactic onlay and sublay mesh reinforcement versus primary suture only in midline laparotomies (PRIMA): 2-year follow-up of a multicentre, double-blind, randomised controlled trial. Lancet. 2017;390(10094):567–76.
pubmed: 28641875 doi: 10.1016/S0140-6736(17)31332-6
Burger JWA, Luijendijk RW, Hop WCJ, et al. Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia. Ann Surg. 2004:578–85.
Holihan JL, Askenasy EP, Greenberg JA, et al. Component separation vs. bridged repair for large ventral hernias: a multi-institutional risk-adjusted comparison, systematic review, and meta-analysis. Surg Infect (Larchmt). 2016;17(1):17–26.
doi: 10.1089/sur.2015.124
Maloney SR, Schlosser KA, Prasad T, et al. Twelve years of component separation technique in abdominal wall reconstruction. Surgery. 2019;166(4):435–44.
pubmed: 31358348 doi: 10.1016/j.surg.2019.05.043
Booth JH, Garvey PB, Baumann DP, et al. Primary fascial closure with mesh reinforcement is superior to bridged mesh repair for abdominal wall reconstruction. J Am Coll Surg. 2013;217(6):999–1009.
pubmed: 24083910 doi: 10.1016/j.jamcollsurg.2013.08.015
Ramirez OM, Ruas E, Dellon AL. “Components separation” method for closure of abdominal-wall defects: an anatomic and clinical study. Plast Reconstr Surg. 1990;86(3):519–26.
pubmed: 2143588 doi: 10.1097/00006534-199009000-00023
Novitsky YW, Elliott HL, Orenstein SB, Rosen MJ. Transversus abdominis muscle release: a novel approach to posterior component separation during complex abdominal wall reconstruction. Am J Surg. 2012;204(5):709–16.
pubmed: 22607741 doi: 10.1016/j.amjsurg.2012.02.008
Deerenberg EB, Timmermans L, Hogerzeil DP, et al. A systematic review of the surgical treatment of large incisional hernia. Hernia. 2015:89–101.
De Vries Reilingh TS, Van Goor H, Rosman C, et al. “Components separation technique” for the repair of large abdominal wall hernias. J Am Coll Surg. 2003;196(1):32–7.
pubmed: 12517546 doi: 10.1016/S1072-7515(02)01478-3
Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324(17):1186–94.
pubmed: 2011163 doi: 10.1056/NEJM199104253241707
Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord. 1997;12(1):89–94.
pubmed: 8990059 doi: 10.1002/mds.870120115
Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Investig Ophthalmol. 1973;12(12):924–7.
U.S. Food & Drug Administration. http://www.fda.gov . Accessed March 19, 2020
Yi DJ, Hwang S, Son J, Yushmanova I, Spenta KA, St. Rose S. Real-world safety and effectiveness of onabotulinumtoxina treatment of crow’s feet lines and glabellar lines: results of a Korean postmarketing surveillance study. Clin Cosmet Investig Dermatol. 2019;12:851–6.
pubmed: 31819582 pmcid: 6875486 doi: 10.2147/CCID.S227493
Santoro A, Copetti M, Miscio AM, Leone MA, Fontana A (2020) Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurol Sci
Escuder AG, Hunter DG. The role of botulinum toxin in the treatment of strabismus. Semin Ophthalmol. 2019:198–204.
Dressler D. Therapeutically relevant features of botulinum toxin drugs. Toxicon. 2020;175:64–8.
pubmed: 32056697 doi: 10.1016/j.toxicon.2019.12.005
Hughes AJ. Botulinum toxin in clinical practice. Drugs. 1994;48(6):888–93.
pubmed: 7533696 doi: 10.2165/00003495-199448060-00005
Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. Toxins (Basel). 2016;8(3):65.
doi: 10.3390/toxins8030065
Ibarra-Hurtado TR, Nuño-Guzmán CM, Echeagaray-Herrera JE, Robles-Vélez E, de Jesús González-Jaime J. Use of botulinum toxin type A before abdominal wall hernia reconstruction. World J Surg. 2009;33(12):2553–6.
pubmed: 19771472 doi: 10.1007/s00268-009-0203-3
Ibarra-Hurtado TR, Nuño-Guzmán CM, Miranda-Díaz AG, Troyo-Sanromán R, Navarro-Ibarra R, Bravo-Cuéllar L. Effect of botulinum toxin type A in lateral abdominal wall muscles thickness and length of patients with midline incisional hernia secondary to open abdomen management. Hernia. 2014;18(5):647–52.
pubmed: 25033942 doi: 10.1007/s10029-014-1280-2
Zendejas B, Khasawneh MA, Srvantstyan B, Jenkins DH, Schiller HJ, Zielinski MD. Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg. 2013;37(12):2830–7.
pubmed: 24081529 doi: 10.1007/s00268-013-2211-6
Farooque F, Jacombs ASW, Roussos E, et al. Preoperative abdominal muscle elongation with botulinum toxin A for complex incisional ventral hernia repair. ANZ J Surg. 2016;86(1–2):79–83.
pubmed: 26245344 doi: 10.1111/ans.13258
Rodriguez-Acevedo O, Elstner KE, Jacombs ASW, et al. Preoperative botulinum toxin A enabling defect closure and laparoscopic repair of complex ventral hernia. Surg Endosc. 2018;32(2):831–9.
pubmed: 28733748 doi: 10.1007/s00464-017-5750-3
Bueno Lledó J, Torregrosa-Gallud A. Preoperative btulinum toxin and progressive pneumoperitoneum are useful in the treatment of large incisional hernias. Am Surg. 2019;85(4):e189–92.
pubmed: 31043210 doi: 10.1177/000313481908500402
Elstner KE, Read JW, Saunders J, et al. Selective muscle botulinum toxin A component paralysis in complex ventral hernia repair. Hernia. 2020;24(2):287–93.
pubmed: 30949893 doi: 10.1007/s10029-019-01939-3
Nielsen M, Bjerg J, Dorfelt A, Jørgensen LN, Jensen KK. Short-term safety of preoperative administration of botulinum toxin A for the treatment of large ventral hernia with loss of domain. Hernia. 2020;24(2):295–9.
pubmed: 31041556 doi: 10.1007/s10029-019-01957-1
Chan DL, Ravindran P, Fan HS, et al. Minimally invasive Venetian blinds ventral hernia repair with botulinum toxin chemical component separation. ANZ J Surg. 2020;90(1–2):67–71.
pubmed: 31566297 doi: 10.1111/ans.15438
Deerenberg EB, Elhage SA, Shao JM, et al. The effects of preoperative botulinum toxin A injection on fascial closure, component separation techniques, and complications in abdominal wall reconstruction. J Surg Res. 2020.
Bueno-Lledó J, Torregrosa A, Ballester N, et al. Preoperative progressive pneumoperitoneum and botulinum toxin type A in patients with large incisional hernia. Hernia. 2017;21(2):233–43.
pubmed: 28124308 doi: 10.1007/s10029-017-1582-2
Smoot D, Zielinski M, Jenkins D, Schiller H. Botox A injection for pain after laparoscopic ventral hernia: a case report. Pain Med. 2011;12(7):1121–3.
pubmed: 21668748 doi: 10.1111/j.1526-4637.2011.01147.x
Bress A, Metzler S, Plastaras C, Nguyen C, Schuster JMJ, Pukenas B. “Scout No Scan” technique reduces patient radiation exposure during CT-guided spine biopsy. AJR Am J Roentgenol. 2017;209(5):1158–61.
pubmed: 28834446 doi: 10.2214/AJR.16.17404
Bueno-Lledó J, Torregrosa A, Jiménez R, Pastor PG. Preoperative combination of progressive pneumoperitoneum and botulinum toxin type A in patients with loss of domain hernia. Surg Endosc. 2018;32(8):3599–608.
pubmed: 29450631 doi: 10.1007/s00464-018-6089-0
Schlosser KA, Maloney SR, Prasad T, Colavita PD, Augenstein VA, Heniford BT. Three-dimensional hernia analysis: the impact of size on surgical outcomes. Surg Endosc. 2020;34(4):1795–801.
pubmed: 31236720 doi: 10.1007/s00464-019-06931-7
Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1–2):65–9.
pubmed: 25613637 doi: 10.1159/000370245
Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296(20):2476–9.
pubmed: 17119144 doi: 10.1001/jama.296.20.2476
Lee KC, Pascal AB, Halepas S, Koch A. What are the most commonly reported complications with cosmetic botulinum toxin type A treatments? J Oral Maxillofac Surg. 2020;(March):1–9.
Ferreira PH, Ferreira ML, Nascimento DP, Pinto RZ, Franco MR, Hodges PW. Discriminative and reliability analyses of ultrasound measurement of abdominal muscles recruitment. Man Ther. 2011;16(5):463–9.
pubmed: 21398167 doi: 10.1016/j.math.2011.02.010

Auteurs

Eva B Deerenberg (EB)

Division of Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Carolinas Medical Center, 1025 Morehead Medical Drive, Suite 300, Charlotte, NC, 28204, USA. eva.b.deerenberg@gmail.com.

Sharbel A Elhage (SA)

Division of Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Carolinas Medical Center, 1025 Morehead Medical Drive, Suite 300, Charlotte, NC, 28204, USA.

Robert J Raible (RJ)

Charlotte Radiology, 700 E Morehead St, Charlotte, NC, 28202, USA.

Jenny M Shao (JM)

Division of Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Carolinas Medical Center, 1025 Morehead Medical Drive, Suite 300, Charlotte, NC, 28204, USA.

Vedra A Augenstein (VA)

Division of Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Carolinas Medical Center, 1025 Morehead Medical Drive, Suite 300, Charlotte, NC, 28204, USA.

B Todd Heniford (BT)

Division of Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Carolinas Medical Center, 1025 Morehead Medical Drive, Suite 300, Charlotte, NC, 28204, USA.

Robert Lopez (R)

Charlotte Radiology, 700 E Morehead St, Charlotte, NC, 28202, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH